Cell & Gene Therapy drug Delivery Devices Market to Grow with a CAGR of 9.85% through 2030

Rising Prevalence of Chronic and Genetic Diseases and Government and Institutional Support are expected to drive the Global Cell & Gene Therapy drug Delivery Devices Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Cell & Gene Therapy drug Delivery Devices Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Cell & Gene Therapy drug Delivery Devices Market stood at USD 1.15 Billion in 2024 and is anticipated to grow with a CAGR of 9.85 in the forecast period, 2026-2030.

The growth of the Global Cell & Gene Therapy (CGT) Drug Delivery Devices Market is being strongly influenced by three interrelated drivers: the expanding therapeutic pipeline, rapid technological innovation, and the structural evolution of global healthcare delivery models.

The rising number of regulatory approvals and active clinical trials for CGTs is a central force accelerating market growth. Therapies such as CAR-T cell treatments, CRISPR-based gene editing platforms, and gene replacement therapies are no longer limited to research settings they are now making measurable inroads into frontline care for oncology, rare genetic disorders, and chronic conditions. This rapid therapeutic expansion is directly increasing demand for a new class of precision delivery tools, including Electroporation devices for ex vivo gene delivery, Intravenous catheters tailored for cell infusions, Prefilled syringes designed for genetic payloads, Intratumoral and intrathecal injection systems for localized administration. As CGTs scale from lab to market, stakeholders are prioritizing delivery systems that meet global regulatory standards, support sterile processing, and ensure safe, reproducible dosing across diverse care settings.

Cutting-edge advances in drug delivery system design are redefining how CGTs are administered. A wave of innovation is enabling more targeted, less invasive, and operationally efficient delivery solutions, with examples including Nanoparticle-based vectors for enhanced gene targeting and intracellular delivery. Microneedle patches for transdermal gene therapy applications. Sensor-integrated infusion pumps capable of real-time dosing analytics and patient monitoring. Next-generation viral and non-viral vectors engineered for greater payload precision and reduced immunogenicity. These technologies are not only improving therapeutic outcomes by boosting bioavailability and minimizing adverse responses but also aligning with regulatory expectations around safety, traceability, and dose control. The convergence of medtech and biotech is driving the development of intelligent, miniaturized platforms optimized for the specific demands of CGT protocols.

The traditional model of centralized, inpatient therapy is giving way to decentralized, outpatient, and even home-based care delivery a trend that is reshaping requirements for CGT drug delivery devices. As more CGTs become viable for administration outside of tertiary hospitals, the need for user-friendly, portable, and safe delivery systems is intensifying. Compact and ergonomically designed devices for easy handling in non-hospital environments. Single-use and prefilled formats to reduce preparation time and minimize contamination risk. Cold chain-compatible systems with secure, validated temperature control for fragile biologics. These functional shifts are driving demand for delivery platforms that support high compliance, minimal training, and consistent sterility critical for personalized therapies administered in ambulatory or at-home settings.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Cell & Gene Therapy drug Delivery Devices Market.”

The Global Cell & Gene Therapy drug Delivery Devices Market is segmented into type, route of administration, method, regional distribution, and company.

Based on its route of administration, the Intravenous (IV) route of administration segment has emerged as the predominant market leader, Cell and gene therapies often involve sensitive biological components including autologous or allogeneic cells, viral vectors, or gene-modified biologics that can lose functionality if exposed to harsh physiological environments. The IV route allows these therapies to be introduced directly into circulation, bypassing degradation in the digestive tract or first-pass metabolism in the liver. This ensures maximum bioavailability and functional integrity of the therapeutic payload.

CAR-T therapies, one of the most commercially successful segments of the CGT market, are almost exclusively administered intravenously. This route facilitates precise dose control, rapid systemic reach, and compatibility with infusion centers and transplant units especially critical in oncology and hematology settings where time-sensitive delivery is essential. IV administration benefits from a mature global infrastructure that supports its widespread use. From infusion centers in hospitals to mobile units and outpatient clinics, the healthcare system is already equipped with catheters, infusion pumps, sterile syringes, and cold chain logistics necessary for CGT delivery via this route. This reduces the need for new infrastructure investment and allows for scalable, standardized deployment of therapies.

The Asia Pacific region is poised to experience the fastest growth in the Global Cell & Gene Therapy drug Delivery Devices Market, Several APAC countries particularly China, Japan, South Korea, and Singapore have emerged as hotspots for CGT clinical trials. Accelerated approval pathways and conditional marketing authorizations (e.g., Japan’s PMDA and China’s NMPA reforms), Expanded R&D grant funding and tax incentives for biotech firms, Development of dedicated innovation zones and biopharma hubs, such as Japan’s Kobe Biomedical Innovation Cluster and China’s Greater Bay Area biotech initiatives. This regulatory momentum is not only increasing the number of CGT candidates being tested and approved in the region but also creating demand for compliant, scalable, and high-performance drug delivery devices suited to complex therapies.

Asia Pacific faces a surging incidence of genetic disorders, cancers, and chronic conditions such as hemophilia, thalassemia, and leukemia, which are being targeted by pipeline CGTs. With a population of over 4.3 billion and growing awareness of precision medicine, the region is seeing: Increased screening and diagnosis rates, leading to higher eligibility for cell and gene-based treatments, Government-led rare disease programs supporting CGT adoption, Patient advocacy and cross-border access to advanced therapies. This disease burden creates a strong clinical need for both CGTs and the specialized devices required for their safe and targeted administration, such as cryopreserved infusion systems, prefilled syringes, and subretinal cannulas..

Major companies operating in Global Cell & Gene Therapy drug Delivery Devices Market are:

• Becton, Dickinson, and Company
• Novartis AG
• Amgen Inc.
• Kite Pharma, Inc.
• Pfizer, Inc.
• Bausch & Lomb Incorporated
• Bluebird bio, Inc.
• Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
• Dendreon Pharmaceuticals LLC.
• Helixmith Co., Ltd (ViroMed Co., Ltd)

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Cell & Gene Therapy Drug Delivery Devices Market is entering a pivotal growth phase, propelled by the increasing clinical and commercial adoption of advanced therapies, expanding R&D pipelines, and the rising need for precise, scalable, and regulatory-compliant delivery systems. As cell and gene therapies continue to redefine treatment paradigms for complex and previously untreatable conditions, the demand for innovative delivery technologies will intensify. Market players that can align device innovation with evolving therapeutic protocols, regulatory standards, and decentralized care models will be well-positioned to capture significant value in this high-growth, high-impact segment of the life sciences industry.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Cell & Gene Therapy drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags), By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others), By Method (In Vitro, Ex Vivo), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global Cell & Gene Therapy drug Delivery Devices Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cell & Gene Therapy drug Delivery Devices Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]